Rani Therapeutics Partners with PegBio to Formulate Multiple Oral Obesity Candidates via RaniPill
RANI•Rani Therapeutics will collaborate with PegBio to develop RaniPill oral formulations for multiple obesity and metabolic disease candidates, advancing selected molecules into preclinical and potential clinical stages. This partnership expands Rani’s obesity franchise beyond its RT-114 GLP-1/GLP-2 Phase 1 trial and preclinical semaglutide program, adding new mechanisms of action.
1. Collaboration Details
Rani Therapeutics will collaborate with PegBio Co. Ltd. to develop RaniPill formulations for multiple obesity and metabolic disease candidates from PegBio’s pipeline, focusing on preclinical development and selecting the most promising molecules for clinical advancement.
2. Obesity Franchise Expansion
The partnership broadens Rani’s obesity portfolio beyond its RT-114 GLP-1/GLP-2 dual agonist currently in Phase 1 and its preclinical semaglutide program, adding differentiated mechanisms of action across multiple novel candidates.
3. RaniPill Platform Advantages
The RaniPill oral delivery capsule has demonstrated safety, tolerability and bioavailability comparable to subcutaneous injections in preclinical and clinical studies, positioning Rani to convert injectable therapies into patient-friendly oral treatments.
